产品名称

SD 169

产品货号

Axon 1357 CAS [1670-87-7] MF C9H8N2OMW 160.17 Purity: 99% Soluble in DMSO and Ethanol Description ATP-competitive, orally active inhibitor of p38α MAP kinase (IC50 = 3.2 nM); being 38 fold selective vs against p38β MAP kinase (IC50 = 122 nM) and no inhibitory activity against a panel of other kinases including p38γ MAP kinase, ERK2, JNK-1 and MAPKAPK-2. KEYWORDS: SD 169 | supplier | p38α MAPK inhibitor | SD169 | SD-169 | CAS [1670-87-7] | MAPK | p38-alpha | ATP-competitive | orally active | MAP kinase | ERK2 | JNK1 | MAPKAPK2

产品价格

现货询价，电话：010-67529703

产品规格

产品品牌

axonmedchem

产品概述

产品详情

SD 169

Based on 21 reference(s) in Google Scholar 10 10 21

Axon 1357

CAS [1670-87-7]

MF C9H8N2O
MW 160.17

Purity: 99%
Soluble in DMSO and Ethanol

SD 169

Description

ATP-competitive, orally active inhibitor of p38α MAP kinase (IC50 = 3.2 nM); being 38 fold selective vs against p38β MAP kinase (IC50 = 122 nM) and no inhibitory activity against a panel of other kinases including p38γ MAP kinase, ERK2, JNK-1 and MAPKAPK-2.

KEYWORDS: SD 169 | supplier | p38α MAPK inhibitor | SD169 | SD-169 | CAS [1670-87-7] | MAPK | p38-alpha | ATP-competitive | orally active | MAP kinase | ERK2 | JNK1 | MAPKAPK2

S Medicherla et al. Preventive and Therapeutic Potential of p38α Selective MAPK Inhibitor in NOD Mice with Type 1 Diabetes. J. Pharmacol. Exp. Ther. 2006, 318, 99-107.

Robert R. Myers et al. Inhibition of p38 MAP kinase activity enhances axonal regeneration. Exp. Neurol. 2003, 184(2), 606-614.

J Yang et al. Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma. Leukemia, 2012, 26(9), 2114-2123.

List of publications using SD 169 (Axon 1357) purchased from Axon Medchem

Cell Signaling & Oncology Pain & Inflammation MAPK (p38) MAPK EC 2.7.11.24

MAPK inhibitor (p38α specific)

Chemical name

1H-Indole-5-carboxylic acid amide

Parent CAS No.

[1670-87-7]

产品资料